abstract |
The present disclosure generally identifies patients likely to respond to treatment through targeted TGF-β inhibition with an anti-TGFβ agonist, and involves treating the subject with an anti-TGFβ agonist, triple negative. It relates to a method for treating a patient diagnosed with breast cancer (TNBC). |